A Phase 2 interventional study of MK-1602 and Placebo in Migraine, sponsored by Allergan. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-12-09.
Sponsored by Allergan (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing ubrogepant in Migraine Disorders — 2 open to participants now, 4 under way, 3 of them phase 3. ubrogepant · Migraine Disorders.
Among the 14 studies testing ubrogepant in Migraine Disorders, this one is the 10th largest by enrollment, is one of 2 that started in 2012, is one of 2 in phase 2, and was the 2nd registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →2 of the 14 studies testing ubrogepant in Migraine Disorders are open now, in 2 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Puerto Rico
Ages 6–17
AbbVie · Sites in United States, Puerto Rico
Ages 6–17
By country, each count listing its studies:
ubrogepant: first FDA approval 2019 (UBRELVY). What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 195 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 507 across the 14 interventional studies. Of the 10 that completed or were terminated, 8 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 4 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
55 studies in Migraine Disorders by AbbVie: 9 open now, 13 under way, 7 of them phase 3. Of 40 finished, 32 (80%) have results posted.
Among the 55 studies in Migraine Disorders by AbbVie, this one is the 32nd largest by enrollment of the 41 interventional ones that give a count, is one of 6 that started in 2012, is one of 3 in phase 2, and was the 8th registered.
AbbVie’s Migraine Disorders studies by the year they started, since 2006.
2 of the studies testing ubrogepant in Migraine Disorders that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05125302Phase 3AbbVieStudy to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | 2027-05 |
| NCT06417775Phase 3AbbVieStudy of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies testing ubrogepant in Migraine Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 55 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to characterize the pharmacokinetics of MK-1602 in the treatment of acute migraine, including the influence of demographic and other variables on MK-1602 pharmacokinetics, and to evaluate the relationship between MK-1602 concentrations and efficacy of the drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
the two months prior to screening
reproductive potential with a screening serum β-human chorionic gonadotropin (β-hCG) level consistent with a not-pregnant state, and who agrees to use acceptable
Exclusion Criteria:
resolve spontaneously in less than two hours
has changed during the 3 months prior to screening and during the study
in response to 3 or more classes of drugs (prescription and over-the-counter)
surgery or banding), or presence of a disease that causes malabsorption
other circumstance that might confound the results of the study, or interfere with subject's participation for the full duration of the study
weeks of study, or intent to donate blood products or receive
blood products within 30 days of screening and throughout study
study
in a study with an compound or device, with the exception of MK-1602 Protocol 006
analgesic for migraine relief
attack within the past 2 months
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MK-1602 placebo-matching tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
Drug: Placebo · Drug: Rescue medication
MK-1602 1 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
Drug: MK-1602 · Drug: Rescue medication
MK-1602 10 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
Drug: MK-1602 · Drug: Rescue medication
MK-1602 25 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
Drug: MK-1602 · Drug: Rescue medication
MK-1602 50 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
Drug: MK-1602 · Drug: Rescue medication
MK-1602 100 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
Drug: MK-1602 · Drug: Rescue medication
Three administrations of the same dose of MK-1602 on separate days. All 3 doses are either 1, 10, 25, 50 or 100 mg of MK-1602. Dose 1: Taken at onset of migraine of moderate or severe intensity. Dose 2: Taken the evening before Visit 2. Dose 3: Taken at Visit 2, which is Day 4 post migraine treatment (Dose 1). Dosage form is film coated tablet for oral administration.
Three administrations of placebo for MK-1602 on separate days. Dose 1: Taken at onset of migraine of moderate or severe intensity. Dose 2: Taken the evening before Visit 2. Dose 3: Taken at Visit 2, which is Day 4 post migraine treatment (Dose 1). Dosage form is film coated tablet for oral administration.
If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours, Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\]), anti-emetics, triptans, opiates or other medication not explicitly excluded.
Dry Blood Spot (DBS) MK-1602 Concentration at 2 Hours Post-Dose on Migraine Treatment Day
The participant collected blood by fingerstick on a card. The card was sent to a laboratory and the concentration of MK-1602 determined using the dried blood spot (DBS) assay.
Time frame: 2 hours post dose 1
Percentage of Participants Reporting Pain Freedom (PF) at 2 Hours Post-Dose on Migraine Treatment Day
PF was defined as a decrease from a moderate or severe migraine headache (Grade 2 or 3) at Baseline to no pain (Grade 0) 2 hours post-dose. Headache severity was reported by the participant using a 4-point scale where: 0=no pain, 1=mild pain, 2=moderate pain and 3=severe pain.
Time frame: 2 hours post dose 1
Percentage of Participants With Pain Relief (PR) at 2 Hours Post-Dose on Migraine Treatment Day
PR was defined as a decrease from a moderate or severe migraine headache (Grade 2 or 3) at Baseline to a mild headache or no headache (Grade 1 or 0) 2 hours post dose. Headache severity was reported by the participant using a 4-point scale where: 0=no pain, 1=mild pain, 2=moderate pain and 3=severe pain.
Time frame: 2 hours post dose 1
Percentage of Participants Reporting Absence of Phonophobia at 2 Hours Post-Dose on Migraine Treatment Day
Phonophobia is sensitivity to sound.
Time frame: 2 hours post dose 1
Percentage of Participants Reporting Absence of Photophobia at 2 Hours Post-Dose on Migraine Treatment Day
Photophobia is sensitivity to light.
Time frame: 2 hours post dose 1
Percentage of Participants Reporting Absence of Nausea at 2 Hours Post-Dose on Migraine Treatment Day
Time frame: 2 hours post dose 1
Percentage of Participants With Sustained Pain Freedom (SPF) From 2-24 Hours Post-Dose on Migraine Treatment Day
SPF was defined as PF at 2 hours post-dose, with no administration of any rescue medication and with no occurrence of a mild/moderate/severe headache during the 2-24 hour period after dosing with study medication.
Time frame: 2-24 hours post dose 1
Percentage of Participants With Sustained Pain Relief (SPR) From 2-24 Hours Post-Dose on Migraine Treatment Day
SPR was defined as PR at 2 hours post-dose, with no administration of any rescue medication and with no occurrence of a moderate/severe headache during the 2-24 hour period after dosing with study medication.
Time frame: 2-24 hours post dose 1
Percentage of Participants With Total Migraine Freedom (TMF) at 2 Hours Post-Dose on Migraine Treatment Day
TMF at 2 hours post-dose was defined as PF with no photophobia, phonophobia, nausea, or vomiting at 2 hours post-dose.
Time frame: 2 hours post dose 1
Percentage of Participants With TMF From 2-24 Hours Post-Dose on Migraine Treatment Day
TMF from 2-24 hours post-dose was defined as SPF with no photophobia, phonophobia, nausea, or vomiting during the 2-24 hour period after dosing with study medication.
Time frame: 2-24 hours post dose 1
Dry Blood Spot (DBS) MK-1602 Concentrations on Migraine Treatment Day
Time frame: Up to 24 hours post dose 1
Dry Blood Spot MK-1602 Concentration at 3.5 Hours Post-Dose at Visit 2 (Day 4)
Time frame: 3.5 hours post dose 3
Plasma MK-1602 Concentrations at Visit 2 (Day 4)
Time frame: Up to 3.5 hours post dose 3
| Milestone | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg |
|---|---|---|---|---|---|---|
| Started | 33 | 32 | 32 | 33 | 34 | 31 |
| Completed | 27 | 28 | 25 | 28 | 27 | 27 |
| Not completed | 6 | 4 | 7 | 5 | 7 | 4 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Physician decision | 2 | 3 | 1 | 2 | 5 | 0 |
| Withdrew: Lack of qualifying event | 1 | 0 | 3 | 2 | 1 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Protocol violation | 1 | 1 | 1 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 1 | 0 | 0 | 1 |
The participant collected blood by fingerstick on a card. The card was sent to a laboratory and the concentration of MK-1602 determined using the dried blood spot (DBS) assay.
| nanomolar (nM) | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg |
|---|---|---|---|---|---|
| Dry Blood Spot (DBS) MK-1602 Concentration at 2 Hours Post-Dose on Migraine Treatment Day | 1.9 ± 73 | 17.0 ± 74 | 43.8 ± 130 | 52.7 ± 270 | 184.8 ± 170 |
PF was defined as a decrease from a moderate or severe migraine headache (Grade 2 or 3) at Baseline to no pain (Grade 0) 2 hours post-dose. Headache severity was reported by the participant using a 4-point scale where: 0=no pain, 1=mild pain, 2=moderate pain and 3=severe pain.
| percentage of participants | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants Reporting Pain Freedom (PF) at 2 Hours Post-Dose on Migraine Treatment Day | 0.0 (0.0 to 12.3) | 0.0 (0.0 to 12.3) | 3.8 (0.1 to 19.6) | 17.9 (6.1 to 36.9) | 28.6 (13.2 to 48.7) | 11.1 (2.4 to 29.2) |
PR was defined as a decrease from a moderate or severe migraine headache (Grade 2 or 3) at Baseline to a mild headache or no headache (Grade 1 or 0) 2 hours post dose. Headache severity was reported by the participant using a 4-point scale where: 0=no pain, 1=mild pain, 2=moderate pain and 3=severe pain.
| percentage of participants | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants With Pain Relief (PR) at 2 Hours Post-Dose on Migraine Treatment Day | 42.9 (24.5 to 62.8) | 42.9 (24.5 to 62.8) | 30.8 (14.3 to 51.8) | 46.4 (27.5 to 66.1) | 67.9 (47.6 to 84.1) | 70.4 (49.8 to 86.2) |
Phonophobia is sensitivity to sound.
| percentage of participants | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants Reporting Absence of Phonophobia at 2 Hours Post-Dose on Migraine Treatment Day | 28.6 (13.2 to 48.7) | 42.9 (24.5 to 62.8) | 30.8 (14.3 to 51.8) | 42.9 (24.5 to 62.8) | 57.1 (37.2 to 75.5) | 44.4 (25.5 to 64.7) |
Photophobia is sensitivity to light.
| percentage of participants | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants Reporting Absence of Photophobia at 2 Hours Post-Dose on Migraine Treatment Day | 25.0 (10.7 to 44.9) | 25.0 (10.7 to 44.9) | 26.9 (11.6 to 47.8) | 28.6 (13.2 to 48.7) | 46.4 (27.5 to 66.1) | 48.1 (28.7 to 68.1) |
| percentage of participants | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants Reporting Absence of Nausea at 2 Hours Post-Dose on Migraine Treatment Day | 67.9 (47.6 to 84.1) | 57.1 (37.2 to 75.5) | 69.2 (48.2 to 85.7) | 57.1 (37.2 to 75.5) | 82.1 (63.1 to 93.9) | 74.1 (53.7 to 88.9) |
SPF was defined as PF at 2 hours post-dose, with no administration of any rescue medication and with no occurrence of a mild/moderate/severe headache during the 2-24 hour period after dosing with study medication.
| percentage of participants | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants With Sustained Pain Freedom (SPF) From 2-24 Hours Post-Dose on Migraine Treatment Day | 0.0 (0.0 to 12.3) | 0.0 (0.0 to 12.3) | 3.8 (0.1 to 19.6) | 10.7 (2.3 to 28.2) | 14.3 (4.0 to 32.7) | 3.7 (0.1 to 19.0) |
SPR was defined as PR at 2 hours post-dose, with no administration of any rescue medication and with no occurrence of a moderate/severe headache during the 2-24 hour period after dosing with study medication.
| percentage of participants | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants With Sustained Pain Relief (SPR) From 2-24 Hours Post-Dose on Migraine Treatment Day | 28.6 (13.2 to 48.7) | 25.0 (10.7 to 44.9) | 15.4 (4.4 to 34.9) | 42.9 (24.5 to 62.8) | 57.1 (37.2 to 75.5) | 48.1 (28.7 to 68.1) |
TMF at 2 hours post-dose was defined as PF with no photophobia, phonophobia, nausea, or vomiting at 2 hours post-dose.
| percentage of participants | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants With Total Migraine Freedom (TMF) at 2 Hours Post-Dose on Migraine Treatment Day | 0.0 (0.0 to 12.3) | 0.0 (0.0 to 12.3) | 0.0 (0.0 to 13.2) | 14.3 (4.0 to 32.7) | 28.6 (13.2 to 48.7) | 7.4 (0.9 to 24.3) |
TMF from 2-24 hours post-dose was defined as SPF with no photophobia, phonophobia, nausea, or vomiting during the 2-24 hour period after dosing with study medication.
| percentage of participants | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants With TMF From 2-24 Hours Post-Dose on Migraine Treatment Day | 0.0 (0.0 to 12.3) | 0.0 (0.0 to 12.3) | 0.0 (0.0 to 13.2) | 10.7 (2.3 to 28.2) | 14.3 (4.0 to 32.7) | 3.7 (0.1 to 19.0) |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/28 (0%) | 6/28 (21.4%) |
| MK-1602 1 mg | — | 0/28 (0%) | 6/28 (21.4%) |
| MK-1602 10 mg | — | 0/26 (0%) | 2/26 (7.7%) |
| MK-1602 25 mg | — | 0/28 (0%) | 10/28 (35.7%) |
| MK-1602 50 mg | — | 0/28 (0%) | 7/28 (25%) |
| MK-1602 100 mg | — | 0/27 (0%) | 7/27 (25.9%) |
| Event | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg |
|---|---|---|---|---|---|---|
| DizzinessNervous system disorders | 4/28 | 2/28 | 0/26 | 2/28 | 0/28 | 2/27 |
| NauseaGastrointestinal disorders | 1/28 | 0/28 | 1/26 | 2/28 | 3/28 | 1/27 |
| Abdominal pain upperGastrointestinal disorders | 0/28 | 1/28 | 0/26 | 0/28 | 2/28 | 2/27 |
| NasopharyngitisInfections and infestations | 1/28 | 1/28 | 0/26 | 1/28 | 0/28 | 2/27 |
| DiarrhoeaGastrointestinal disorders | 0/28 | 0/28 | 0/26 | 2/28 | 1/28 | 0/27 |
| Dry mouthGastrointestinal disorders | 0/28 | 1/28 | 1/26 | 2/28 | 2/28 | 1/27 |
| FatigueGeneral disorders | 1/28 | 0/28 | 0/26 | 2/28 | 0/28 | 0/27 |
| HeadacheNervous system disorders | 0/28 | 2/28 | 0/26 | 0/28 | 0/28 | 0/27 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/28 | 0/28 | 0/26 | 2/28 | 0/28 | 0/27 |
All Subjects as Treated Population included all randomized participants who received at least 1 dose of study treatment.
| Age, Customized(participants) | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg | Total |
|---|---|---|---|---|---|---|---|
| <20 years | 1 | 1 | 0 | 0 | 0 | 2 | 4 |
| 20 to 29 years | 4 | 8 | 6 | 9 | 11 | 9 | 47 |
| 30 to 39 years | 9 | 7 | 7 | 7 | 6 | 6 | 42 |
| 40 to 49 years | 9 | 9 | 7 | 7 | 6 | 6 | 44 |
| 50 to 59 years | 5 | 3 | 4 | 3 | 4 | 3 | 22 |
| 60 to 64 years | 0 | 0 | 0 | 2 | 0 | 1 | 3 |
| >= 65 years | 0 | 0 | 2 | 0 | 1 | 0 | 3 |
| Sex: Female, Male(Participants) | Placebo | MK-1602 1 mg | MK-1602 10 mg | MK-1602 25 mg | MK-1602 50 mg | MK-1602 100 mg | Total |
|---|---|---|---|---|---|---|---|
| Female | 25 | 26 | 22 | 23 | 26 | 18 | 140 |
| Male | 3 | 2 | 4 | 5 | 2 | 9 | 25 |
No study locations are listed for this record.
The record gives a start of Aug 2012, a primary completion of Nov 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2016, 4 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ubrogepant